Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

MediGus Ltd.

This article was originally published in Start Up

Executive Summary

MediGus Ltd. combines an endoscopic stapler with a miniaturized ultrasonic sighting system in a tool designed to permit surgeons to convert open or laparoscopic surgeries to least-invasive endoscopic surgeries.

You may also be interested in...



The New Wave in Gastroenterology

Gastroenterology, once a market comprised of large, reusable pieces of equipment like endoscopes, ushers in a new era of minimally invasive surgical disposables. Indeed, minimally invasive procedures make it possible for surgical devices to encroach upon drug franchises in several multi-billion dollar markets, including gastroesophageal reflux disease and obesity.

A Gut Feeling

The gastrointestinal market has traditionally split into two categories: the heartburn diseases GERD and ulcer, and "other." The former category has yielded blockbuster successes for several large companies, including SmithKline Beecham and AstraZeneca. Those markets have plateaued, however, and now companies are casting about for follow-on products in GI. Large companies and small companies have begun to venture into the "other" GI diseases, irritable bowel syndrome, and inflammatory bowel disease. These diseases are all difficult to diagnose, and the mechanisms that underpin them are still unknown. Furthermore, the diseases are multi-factorial, immunological inflammatory diseases and drug discovery is challenging. While waiting for new drugs, many small companies find the market controlled by 10,000 gastroenterologists in the US to be a niche opportunity that represents a large market that can be targeted with a small salesforce. Device companies too have a role to play, in giving gastros new procedures that keep patients in their franchise, which is encroached upon by GPs and general surgeons.

UK Grants First Worldwide Authorization For PfIzer/BioNTech COVID-19 Vaccine

The UK has approved the mRNA-based vaccine just nine days after receiving the final Phase III results from Pfizer.

Topics

Related Companies

UsernamePublicRestriction

Register

OM009163

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel